Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MBX
HOLDMBX Biosciences, Inc. · Healthcare · United States · $3.0B · Avg Vol: $60M/d
COMPANY DESCRIPTION
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare endocrine diseases with high unmet medical needs. The company's competitive moat lies in its specialized focus on these underserved patient populations and its proprietary drug development platform designed to address complex hormonal imbalances. MBX aims to secure orphan drug designations, potentially leading to expedited development pathways and market exclusivity for its novel treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.82 | -1.02 | -5.82 | -2.38 | — | -2.08 | -2.71 | -3.60 | — |
| Shares | 31.9M | 31.9M | 33.4M | 44.9M | +41.0% | 47.6M | — | — | — |
| Debt | 0.5M | 0.3M | 0.2M | 0.6M | 8.9% | 0.6M | — | — | — |
| Equity | -42.6M | -72.5M | 257.4M | 369.2M | 43.4% | — | — | — | — |
| Op CF | -23.1M | -32.0M | -54.7M | -79.9M | — | -77.5M | — | — | — |
| Inv CF | -11.4M | -30.9M | -160.6M | -83.7M | — | — | — | — | — |
| Fin CF | 46.1M | 69.2M | 234.1M | 189.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MBX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MBX | MBX Biosciences, Inc.(you) | $3.0B | 40 | HOLD |
| MRVI | Maravai LifeSciences Holdings, Inc. | $2.5B | 42 | HOLD |
| TRVI | Trevi Therapeutics, Inc. | $2.5B | 36 | HOLD |
| SLS | SELLAS Life Sciences Group, Inc. | $2.2B | 37 | HOLD |
| ELVN | Enliven Therapeutics, Inc. | $3.8B | 44 | HOLD |
| IOVA | Iovance Biotherapeutics, Inc. | $2.2B | 35 | SELL |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.4B | 32 | SELL |
| DYN | Dyne Therapeutics, Inc. | $4.0B | 35 | HOLD |
| ATAI | AtaiBeckley Inc. | $2.7B | 31 | SELL |
| AGIO | Agios Pharmaceuticals, Inc. | $2.2B | 34 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%